4.7 Article

Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer

Journal

CLINICAL CANCER RESEARCH
Volume 25, Issue 17, Pages 5351-5363

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-18-4192

Keywords

-

Categories

Funding

  1. Halozyme
  2. NIH [T32 CA126607, R01 CA169702, K23 CA148964, R01 CA197296]
  3. Viragh Foundation
  4. Skip Viragh Pancreatic Cancer Center at Johns Hopkins
  5. Sol Goldman Pancreatic Cancer Research Center
  6. Lefkofsky Family Foundation
  7. National Cancer Institute Specialized Programs of Research Excellence in Gastrointestinal Cancers grant [P50 CA062924]
  8. Sidney Kimmel Comprehensive Cancer Center grant [P30 CA006973]
  9. Lustgarten Foundation grant

Ask authors/readers for more resources

Purpose: Myeloid cells are a prominent immunosuppressive component within the stroma of pancreatic ductal adenocarcinoma (PDAC). Previously, targeting myeloid cells has had limited success. Here, we sought to target the myeloid cells through modifying a specific stromal component. Experimental Design: A murine model of metastatic PDAC treated with an irradiated whole-cell PDAC vaccine and PDAC specimens from patients treated with the same type of vaccine were used to assess the immune-modulating effect of stromal hyaluronan (HA) degradation by PEGPH20. Results: Targeting stroma by degrading HA with PEGPH20 in combination with vaccine decreases CXCL12/CXCR4/CCR7 immunosuppressive signaling axis expression in cancer-associated fibroblasts, myeloid, and CD8(+)T cells, respectively. This corresponds with increased CCR7(-) effector memory T-cell infiltration, an increase in tumor-specific IFN gamma, and improved survival. In the stroma of human PDACs treated with the same vaccine, decreased stromal CXCR4 expression significantly correlated with decreased HA and increased cytotoxic activities, suggesting CXCR4 is an important therapeutic target. Conclusions: This study represents the first to dissect signaling cascades following PDAC stroma remodeling via HA depletion, suggesting this not only overcomes a physical barrier for immune cell trafficking, but alters myeloid function leading to downstream selective increases in effector memory T-cell infiltration and antitumor activity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

Julie E. Stein, Evan J. Lipson, Tricia R. Cottrell, Patrick M. Forde, Robert A. Anders, Ashley Cimino-Mathews, Elizabeth D. Thompson, Mohamad E. Allaf, Mark Yarchoan, Josephine Feliciano, Hao Wang, Elizabeth M. Jaffee, Drew M. Pardoll, Suzanne L. Topalian, Janis M. Taube

CLINICAL CANCER RESEARCH (2020)

Editorial Material Medicine, Research & Experimental

Disrupting a converging metabolic target turns up the immunologic-heat in pancreatic tumors

Won Jin Ho, Elizabeth M. Jaffee

JOURNAL OF CLINICAL INVESTIGATION (2020)

Letter Behavioral Sciences

Efficacy of Electroconvulsive Therapy for Treatment-Resistant Depression Caused by Hyperparathyroidism A Case Report

Yoshihiro Matsumoto, Nobutaka Ayani, Yoshinari Abe, Chikara Nakayama, Takahiro Tsujikawa, Masaya Oda, Jin Narumoto

JOURNAL OF ECT (2020)

Article Oncology

Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer

Nitya Nair, Shih-Yu Chen, Ed Lemmens, Serena Chang, Dung T. Le, Elizabeth M. Jaffee, Aimee Murphy, Chan Whiting, Thomas Mueller, Dirk G. Brockstedt

CANCER IMMUNOLOGY RESEARCH (2020)

Article Biotechnology & Applied Microbiology

Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors

Hanwen Wang, Richard J. Sove, Mohammad Jafarnejad, Sondra Rahmeh, Elizabeth M. Jaffee, Vered Stearns, Evanthia T. Roussos Torres, Roisin M. Connolly, Aleksander S. Popel

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2020)

Article Multidisciplinary Sciences

Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer

Preethi Korangath, James D. Barnett, Anirudh Sharma, Elizabeth T. Henderson, Jacqueline Stewart, Shu-Han Yu, Sri Kamal Kandala, Chun-Ting Yang, Julia S. Caserto, Mohammad Hedayati, Todd D. Armstrong, Elizabeth Jaffee, Cordula Gruettner, Xian C. Zhou, Wei Fu, Chen Hu, Saraswati Sukumar, Brian W. Simons, Robert Ivkov

SCIENCE ADVANCES (2020)

Article Oncology

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma

Won Jin Ho, Ludmila Danilova, Su Jin Lim, Rohan Verma, Stephanie Xavier, James M. Leatherman, Marcelo B. Sztein, Elana J. Fertig, Hao Wang, Elizabeth Jaffee, Mark Yarchoan

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Cell Biology

Cancer cells educate natural killer cells to a metastasis-promoting cell state

Isaac S. Chan, Hildur Knutsdottir, Gayathri Ramakrishnan, Veena Padmanaban, Manisha Warrier, Juan Carlos Ramirez, Matthew Dunworth, Hao Zhang, Elizabeth M. Jaffee, Joel S. Bader, Andrew Josef Ewald

JOURNAL OF CELL BIOLOGY (2020)

Article Medicine, Research & Experimental

Effects of B cell-activating factor on tumor immunity

Mark Yarchoan, Won Jin Ho, Aditya Mohan, Yajas Shah, Teena Vithayathil, James Leatherman, Lauren Dennison, Neeha Zaidi, Sudipto Ganguly, Skylar Woolman, Kayla Cruz, Todd D. Armstrong, Elizabeth M. Jaffee

JCI INSIGHT (2020)

Article Oncology

Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)

Evanthia T. Roussos Torres, Christine Rafie, Chenguang Wang, David Lim, Adam Brufsky, Patricia LoRusso, Joseph Paul Eder, Vincent Chung, Melinda Downs, Molly Geare, Richard Piekarz, Howard Streicher, Leslie Anforth, Michelle A. Rudek, Qingfeng Zhu, Sepideh Besharati, Ashley Cimino-Mathews, Robert A. Anders, Vered Stearns, Elizabeth M. Jaffee, Roisin M. Connolly

Summary: This study investigated the efficacy and safety of combining the histone deacetylase inhibitor entinostat with nivolumab +/- ipilimumab in advanced solid tumors. The results showed that this combination therapy had promising clinical efficacy, with a significant increase in CD8/FoxP3 ratio, indicating potential for further research. The study concluded that the combination was safe and well tolerated, supporting the need for further investigation into both clinical efficacy and immune modulation.

CLINICAL CANCER RESEARCH (2021)

Article Oncology

Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment

Dimitrios N. Sidiropoulos, Christine I. Rafie, Julie K. Jang, Sofi Castanon, Aaron G. Baugh, Edgar Gonzalez, Brian J. Christmas, Valerie H. Narumi, Emily F. Davis-Marcisak, Gaurav Sharma, Emma Bigelow, Ajay Vaghasia, Anuj Gupta, Alyza Skaist, Michael Considine, Sarah J. Wheelan, Sathish Kumar Ganesan, Min Yu, Srinivasan Yegnasubramanian, Vered Stearns, Roisin M. Connolly, Daria A. Gaykalova, Luciane T. Kagohara, Elizabeth M. Jaffee, Elana J. Fertig, Evanthia T. Roussos Torres

Summary: This study comprehensively characterized the changes in the tumor microenvironment (TME) induced by entinostat, an oral histone deacetylase inhibitor, using single-cell RNA sequencing. The results showed that entinostat shifted the TME from a protumor to an antitumor signature, mainly through changes in myeloid cells. This study suggests that entinostat-induced alterations in myeloid cell types reduce immunosuppression and increase antitumor responses, thus improving the sensitivity to immune checkpoint inhibitors (ICIs).

CANCER IMMUNOLOGY RESEARCH (2022)

Article Oncology

Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide

Adam C. Mirando, Akash Patil, Christine I. Rafie, Brian J. Christmas, Niranjan B. Pandey, Vered Stearns, Elizabeth M. Jaffee, Evanthia T. Roussos Torres, Aleksander S. Popel

ONCOIMMUNOLOGY (2020)

Article Oncology

Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future

Eric S. Christenson, Elizabeth Jaffee, Nilofer S. Azad

LANCET ONCOLOGY (2020)

Meeting Abstract Oncology

NF-kB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma.

Rahul R. Suresh, David J. Barakat, Theresa Barberi, Lei Zheng, Elizabeth M. Jaffee, Kenneth J. Pienta, Alan D. Friedman

CANCER IMMUNOLOGY RESEARCH (2020)

Article Medicine, Research & Experimental

Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes

Won Jin Ho, Mark Yarchoan, Soren Charmsaz, Rebecca M. Munday, Ludmila Danilova, Marcelo B. Sztein, Elana J. Fertig, Elizabeth M. Jaffee

JCI INSIGHT (2020)

No Data Available